A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgen-Independent Prostatic Cancer
Androgen-Independent Prostatic Neoplasms
Prostate Cancer Recurrent
Androgen-Insensitive Prostatic Cance
Androgen-Resistant Prostatic Cancer
Hormone Refractory Prostatic Cancer
Immunotherapy
Immune Checkpoint Inhibitor
Inhibitory Checkpoint Molecule

Interventions

BIOLOGICAL: lorigerlimab
DRUG: docetaxel
DRUG: Prednisone

Sponsor

MacroGenics